Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1963 1
1964 2
1965 1
1966 2
1967 1
1968 3
1969 5
1970 6
1971 8
1972 13
1973 12
1974 8
1975 27
1976 39
1977 34
1978 41
1979 38
1980 53
1981 47
1982 37
1983 38
1984 30
1985 43
1986 29
1987 40
1988 50
1989 45
1990 29
1991 51
1992 31
1993 55
1994 39
1995 42
1996 41
1997 50
1998 44
1999 55
2000 63
2001 59
2002 60
2003 63
2004 78
2005 75
2006 75
2007 98
2008 84
2009 99
2010 133
2011 228
2012 242
2013 302
2014 310
2015 377
2016 453
2017 508
2018 516
2019 606
2020 737
2021 779
2022 777
2023 771
2024 296

Text availability

Article attribute

Article type

Publication date

Search Results

7,790 results

Results by year

Filters applied: . Clear all
Page 1
Prehospital Tranexamic Acid for Severe Trauma.
PATCH-Trauma Investigators and the ANZICS Clinical Trials Group; Gruen RL, Mitra B, Bernard SA, McArthur CJ, Burns B, Gantner DC, Maegele M, Cameron PA, Dicker B, Forbes AB, Hurford S, Martin CA, Mazur SM, Medcalf RL, Murray LJ, Myles PS, Ng SJ, Pitt V, Rashford S, Reade MC, Swain AH, Trapani T, Young PJ. PATCH-Trauma Investigators and the ANZICS Clinical Trials Group, et al. N Engl J Med. 2023 Jul 13;389(2):127-136. doi: 10.1056/NEJMoa2215457. Epub 2023 Jun 14. N Engl J Med. 2023. PMID: 37314244 Clinical Trial.
At 28 days after injury, 113 of 653 patients (17.3%) in the tranexamic acid group and 139 of 637 (21.8%) in the placebo group had died (risk ratio, 0.79; 95% CI, 0.63 to 0.99). By 6 months, 123 of 648 patients (19.0%) in the tranexamic acid group and 1 …
At 28 days after injury, 113 of 653 patients (17.3%) in the tranexamic acid group and 139 of 637 (21.8%) in the placebo group …
Clinical use of tranexamic acid: evidences and controversies.
Colomina MJ, Contreras L, Guilabert P, Koo M, M Ndez E, Sabate A. Colomina MJ, et al. Braz J Anesthesiol. 2022 Nov-Dec;72(6):795-812. doi: 10.1016/j.bjane.2021.08.022. Epub 2021 Oct 7. Braz J Anesthesiol. 2022. PMID: 34626756 Free PMC article. Review.
Tranexamic acid (TXA) significantly reduces blood loss in a wide range of surgical procedures and improves survival rates in obstetric and trauma patients with severe bleeding. ...Severe events are rare in clinical trials, and literature reviews have shown tranex …
Tranexamic acid (TXA) significantly reduces blood loss in a wide range of surgical procedures and improves survival rates in o …
Tranexamic acid: a clinical review.
Ng W, Jerath A, Wąsowicz M. Ng W, et al. Anaesthesiol Intensive Ther. 2015;47(4):339-50. doi: 10.5603/AIT.a2015.0011. Epub 2015 Mar 23. Anaesthesiol Intensive Ther. 2015. PMID: 25797505 Free article. Review.
The evidence of their efficacy has been mounting for years. Tranexamic acid (TXA), a synthetic lysine-analogue antifibrinolytic, was first patented in 1957 and its use has been increasing in contrast to aprotinin, a serine protease inhibitor antifibrinolytic. ...
The evidence of their efficacy has been mounting for years. Tranexamic acid (TXA), a synthetic lysine-analogue antifibrinolyti …
Tranexamic acid: Beyond antifibrinolysis.
Prudovsky I, Kacer D, Zucco VV, Palmeri M, Falank C, Kramer R, Carter D, Rappold J. Prudovsky I, et al. Transfusion. 2022 Aug;62 Suppl 1:S301-S312. doi: 10.1111/trf.16976. Epub 2022 Jul 14. Transfusion. 2022. PMID: 35834488 Review.
Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma patients and cardiovascular, orthopedic, and gynecological surgical patients. ...
Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma patients and cardiovascular, orthop …
Tranexamic acid in pediatric hemorrhagic trauma.
Borgman MA, Nishijima DK. Borgman MA, et al. J Trauma Acute Care Surg. 2023 Jan 1;94(1S Suppl 1):S36-S40. doi: 10.1097/TA.0000000000003775. Epub 2022 Aug 31. J Trauma Acute Care Surg. 2023. PMID: 36044459 Clinical Trial.
There is strong evidence in adult literature that tranexamic acid (TXA) given within 3 hours from injury is associated with improved outcomes. ...
There is strong evidence in adult literature that tranexamic acid (TXA) given within 3 hours from injury is associated with im …
Tranexamic acid - A narrative review for the emergency medicine clinician.
Wang K, Santiago R. Wang K, et al. Am J Emerg Med. 2022 Jun;56:33-44. doi: 10.1016/j.ajem.2022.03.027. Epub 2022 Mar 22. Am J Emerg Med. 2022. PMID: 35364476 Review.
INTRODUCTION: Over the last decade, tranexamic acid (TXA) has been incorporated into treatment algorithms for a multitude of emergent conditions and the evidence surrounding its role in emergency medicine continues to evolve. ...The role of TXA in other clinical sce …
INTRODUCTION: Over the last decade, tranexamic acid (TXA) has been incorporated into treatment algorithms for a multitude of e …
Microneedling as an adjuvant to topical therapies for melasma: A systematic review and meta-analysis.
Bailey AJM, Li HO, Tan MG, Cheng W, Dover JS. Bailey AJM, et al. J Am Acad Dermatol. 2022 Apr;86(4):797-810. doi: 10.1016/j.jaad.2021.03.116. Epub 2021 Apr 12. J Am Acad Dermatol. 2022. PMID: 33857549
RESULTS: Twelve eligible studies comprising 459 patients from 7 different countries were included. Topical therapies included topical tranexamic acid, vitamin C, platelet-rich plasma, non-hydroquinone-based depigmentation serums, and hydroquinone-based depigmenting …
RESULTS: Twelve eligible studies comprising 459 patients from 7 different countries were included. Topical therapies included topical tra …
Tranexamic acid-associated seizures: Causes and treatment.
Lecker I, Wang DS, Whissell PD, Avramescu S, Mazer CD, Orser BA. Lecker I, et al. Ann Neurol. 2016 Jan;79(1):18-26. doi: 10.1002/ana.24558. Epub 2015 Dec 15. Ann Neurol. 2016. PMID: 26580862 Free PMC article. Review.
Antifibrinolytic drugs are routinely used worldwide to reduce the bleeding that results from a wide range of hemorrhagic conditions. The most commonly used antifibrinolytic drug, tranexamic acid, is associated with an increased incidence of postoperative seizures. . …
Antifibrinolytic drugs are routinely used worldwide to reduce the bleeding that results from a wide range of hemorrhagic conditions. The mos …
Tranexamic acid: still far to go.
Goobie SM. Goobie SM. Br J Anaesth. 2017 Mar 1;118(3):293-295. doi: 10.1093/bja/aew470. Br J Anaesth. 2017. PMID: 28203768 Free article. No abstract available.
7,790 results